



ASX ANNOUNCEMENT

Lumos Diagnostics Annual General Meeting Chair's Address

MELBOURNE, Australia (24 October 2025) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, today release the Chair’s Address for the 2025 Annual General Meeting as follows:

Good morning, everyone. My name is Sam Lanyon, Chair of Lumos Diagnostics Holdings Ltd, and it is my pleasure to welcome you all to our Annual General Meeting of Shareholders.

FY25 was another defining year for Lumos Diagnostics, with the strategic foundations laid over recent years beginning to deliver tangible commercial and operational results.

Personally, it has been pleasing to see Lumos progress from an early-stage business to an emerging global diagnostics company with a clear focus and growing market presence. This progress reflects the disciplined leadership of our CEO and Managing Director, Doug Ward, working with his US and Australian based team, and supported by a Board focused on preparing for the next phase of growth.

Our strategy remains centred on the global commercialisation of FebriDx®, our flagship point-of-care diagnostic test. FebriDx continues to gain traction, particularly in the U.S., where commercial interest and recognition of Lumos as a credible diagnostics partner is building.

Partnerships remain key to our success. During the year, we expanded our FebriDx distribution relationship with Henry Schein, entered into a significant distribution agreement with PHASE Scientific, and continued to strengthen our collaboration with Hologic in the development of its next generation Fetal Fibronectin point-of-care test. These partnerships reflect confidence in our technology, execution, and people.

We also made strong progress on U.S. reimbursement for FebriDx. The product was added to the national Medicare fee schedule, with six of seven Medicare Administrative Contractors now able to provide full reimbursement of US\$41.38 per test. With the support of our new partner, PRO-spectus, we are now focused on engaging private payors and assisting healthcare providers in incorporating reimbursement and the use of FebriDx into their clinical workflows. These early reimbursement wins are important for driving adoption, expanding payor coverage, and reinforcing the long-term commercial value of our technology.

From a capital perspective, Lumos remains well funded. We completed a successful capital raise earlier in the year and also secured a standby loan facility from our major shareholders, Tenmile and Ryder Capital, in order to provide a level of flexibility for our business as we work to deliver on key FY26 milestones. In addition, substantial anticipated non-dilutive milestone payments are payable under our commercial agreements which are expected to further strengthen our financial position.

A major operational achievement in FY25 was the completion of the CLIA waiver trial for FebriDx, a key step in its U.S. regulatory process. Following an enrolment acceleration plan implemented in March, the study concluded successfully, with results that exceeded our targets. The CLIA waiver application has now been submitted to the FDA, and we expect feedback between November 2025 and February 2026. A successful FDA grant will expand our U.S. addressable market by over fifteenfold to more than US\$1 billion.

We acknowledge the valuable support of BARDA, whose partnership has been instrumental in helping Lumos progress through these milestones.

Following year end, in July, Lumos signed a pivotal exclusive U.S. distribution agreement for FebriDx with PHASE Scientific International Limited, a fast-growing biotech company focused on innovative diagnostics and healthcare solutions. Assuming Lumos is granted CLIA waiver for FebriDx and PHASE Scientific meets all payment milestones and minimum order quantities, the agreement has a total potential value of US\$317 million (A\$487 million) over its term. This represents one of the largest distribution deals of its kind by an ASX-listed point-of-care diagnostics company, marking a major milestone in Lumos' history and a significant step forward for the Company's future growth.

Looking to FY26, our focus remains on disciplined execution across both our proprietary products and client partnerships, converting our technical and commercial strengths into sustainable value for shareholders. Importantly, we have now commenced a paediatric study for FebriDx, supported by BARDA, which will run for approximately 12 months. A positive outcome will further expand FebriDx's intended use from the current 12–64 age range to 2–64, significantly broadening its clinical and commercial potential.

On behalf of the Board, I thank our shareholders and commercial partners for your ongoing support and trust. We remain committed to building a sustainable diagnostics business that delivers long-term value.

Finally, I thank our team for their commitment and professionalism, which continue to drive Lumos' progress and position the Company for future success.

Thank you, and I look forward to the year ahead.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary

digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia
H[^]CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
info@lumosdiagnostics.com
+61 3 9087 1598